Search results
Showing 1351 to 1400 of 2053 results for work
In development Reference number: GID-TA11365 Expected publication date: TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
In development Reference number: GID-TA10935 Expected publication date: TBC
In development Reference number: GID-TA11001 Expected publication date: TBC
In development Reference number: GID-TA11582 Expected publication date: TBC
In development Reference number: GID-TA11884 Expected publication date: TBC
Discontinued Reference number: GID-TA10019
This quality standard covers improving the quality of the patient experience for people who use adult NHS services. It describes high-quality care in priority areas for improvement.
View quality statements for QS15Show all sections
Sections for QS15
- Quality statements
- Quality statement 1: Empathy, dignity and respect
- Quality statement 2: Contacts for ongoing care
- Quality statement 3: Information exchange
- Quality statement 4: Individualised care
- Quality statement 5: Preferences for sharing information
- Quality statement 6: Decision making
- Update information
This quality standard covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover areas of national policy, such as the UK Bacillus Calmette-Guérin (BCG) immunisation programme.
View quality statements for QS141Show all sections
Sections for QS141
- Quality statements
- Quality statement 1: Latent tuberculosis testing for people from high-incidence countries
- Quality statement 2: Latent tuberculosis testing for adults with HIV
- Quality statement 3: Rapid diagnosis of pulmonary tuberculosis
- Quality statement 4: Assessment
- Quality statement 5: Directly observed therapy
- Quality statement 6: Accommodation
- Update information
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]
Discontinued Reference number: GID-TA10722
In development Reference number: GID-TA11586 Expected publication date: TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development Reference number: GID-TA10555 Expected publication date: TBC
In development Reference number: GID-TA11366 Expected publication date: TBC
Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]
Discontinued Reference number: GID-TAG431
Discontinued Reference number: GID-TAG456
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]
Discontinued Reference number: GID-TA10306
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Generalised anxiety disorder and panic disorder in adults: management (CG113)
This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.
Discontinued Reference number: GID-TA10390
In development Reference number: GID-TA10667 Expected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
In development Reference number: GID-TA11253 Expected publication date: TBC
Clostridium difficile associated diarrhoea - tolevamer [ID378]
Discontinued Reference number: GID-TAG389
In development Reference number: GID-TA11486 Expected publication date: TBC
In development Reference number: GID-TA11690 Expected publication date: TBC
In development Reference number: GID-TA11663 Expected publication date: TBC
Discontinued Reference number: GID-TA10018
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070
Discontinued Reference number: GID-TAG360
Discontinued Reference number: GID-TA10234
In development Reference number: GID-TA11021 Expected publication date: TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]
In development Reference number: GID-TA11265 Expected publication date: TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
In development Reference number: GID-TA11368 Expected publication date: TBC
Botulinum toxin type A for preventing episodic migraine [ID6450]
In development Reference number: GID-TA11505 Expected publication date: TBC
In development Reference number: GID-TA11401 Expected publication date: TBC
For which people with impetigo are antiseptics as effective as antibiotics?
A faster recovery is also likely to mean less time off school, nursery or work. It was not clear in the evidence reviewed if impetigo...
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued Reference number: GID-HST10038
Nintedanib for untreated malignant pleural mesothelioma [ID1424]
Discontinued Reference number: GID-TA10359
In development Reference number: GID-TA11089 Expected publication date: TBC
In development Reference number: GID-TA11299 Expected publication date: TBC
Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.
Discontinued Reference number: GID-TA10353
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]
Discontinued Reference number: GID-TA10355
Discontinued Reference number: GID-TAG280
Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]
Discontinued Reference number: GID-TA10585
Masitinib for treating amyotrophic lateral sclerosis [ID967]
Discontinued Reference number: GID-TA10157
In development Reference number: GID-TA11607 Expected publication date: 13 January 2027